An asymmetrical CLL1/CD3 bispecific antibody, ABL602, exhibits CLL1 binding-dependent CD3 binding/activation and antitumor activity in acute myeloid leukemia (AML) mouse model and leukemia blasts from AML patients

被引：1
|
作者：
Lee, E. [1 ]
Lim, Y. [1 ]
Lee, S. [1 ]
Park, S. [1 ]
Park, H. [1 ]
Koh, Y. [2 ]
Shin, D. [2 ]
Won, J. [1 ]
机构：
[1] ABL Bio Inc, Early Res Dev, Seongnam, South Korea
[2] SNUH Seoul Natl Univ Hosp, Hematol Oncol Dept, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.748
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
622MO
引用
收藏
页码：S828 / S829
页数：2
相关论文
共 20 条
  • [1] Asymmetric anti-CLL-1xCD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
    Lee, Eunhee
    Lee, Shinai
    Park, Sumyeong
    Son, Yong-Gyu
    Yoo, Jiseon
    Koh, Youngil
    Shin, Dong-Yeop
    Lim, Yangmi
    Won, Jonghwa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
  • [2] Intracellular retention of TCRαβ/CD3 to generate novel allogeneic CAR-T cells targeting CLL1 for treating acute myelocytic leukemia
    Li, Jun
    Liu, Kaichun
    Xu, Guanggui
    Chen, Shanshan
    Zhang, Yinhang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Anti-IL1RAP/CD3 Bispecific Antibody (BsAb) Is a Promising Novel and Effective Therapy for Acute Myeloid Leukemia (AML)
    Meng, Weixu
    Del Real, Marissa
    Wei, Guowei
    Hernandez, Rochelle
    Marcucci, Emanuela
    Lin, Allen
    Mcdonald, Tinisha
    Zhao, Dandan
    Wu, Herman
    Carlesso, Nadia
    Kwak, Larry W.
    Li, Ling
    Kuo, Ya-Huei
    Stein, Anthony S.
    Pullarkat, Vinod
    Nakamura, Ryotaro
    Rosen, Steven T.
    Forman, Stephen J.
    Zhang, Bin
    Budde, Lihua
    Marcucci, Guido
    BLOOD, 2017, 130
  • [4] Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1 x CD3 BiTE Antibody
    Noordhuis, Paul
    Terwijn, Monique
    Rutten, Arjo P.
    Smit, Linda
    Ossenkoppele, Gert J.
    Schuurhuis, Gerrit J.
    BLOOD, 2010, 116 (21) : 1191 - 1191
  • [5] An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
    Leong, Steven R.
    Sukumaran, Siddharth
    Hristopoulos, Maria
    Totpal, Klara
    Stainton, Shannon
    Lu, Elizabeth
    Wong, Alfred
    Tam, Lucinda
    Newman, Robert
    Vuillemenot, Brian R.
    Ellerman, Diego
    Gu, Chen
    Mathieu, Mary
    Dennis, Mark S.
    Nguyen, Allen
    Zheng, Bing
    Zhang, Crystal
    Lee, Genee
    Chu, Yu-Waye
    Prell, Rodney A.
    Lin, Kedan
    Laing, Steven T.
    Polson, Andrew G.
    BLOOD, 2017, 129 (05) : 609 - 618
  • [6] A Novel Asymmetrical Anti-CLL-1xCD3 Bispecific Antibody, ABL602, Induces Potent CLL1-Specific Antitumor Activity with Minimized Sensitization of Pro-Inflammatory Cytokines
    Lim, Yangmi
    Lee, Eunhee
    Lee, Shinai
    Park, Sumyeong
    Park, Hyeyoung
    Won, Jonghwa
    BLOOD, 2021, 138
  • [7] Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Hutchings, Martin
    Montesinos, Pau
    Santoro, Armando
    Hou, Hsin-An
    Martinez-Sanchez, Maria Pilar
    Vives, Susana
    Galimberti, Sara
    Chen, Tsai-Yun
    Frigeni, Marco
    Garciaz, Sylvain
    Salamero, Olga
    Yeh, Su-Peng
    Yee, Karen
    Schnetzler, Gabriel
    Barata, Teresa
    Simon, Silke
    Hinton, Heather
    Korfi, Koorosh
    Richard, Muriel
    Keshelava, Nino
    Subklewe, Marion
    BLOOD, 2023, 142
  • [8] Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
    Uy, Geoffrey L.
    Aldoss, Ibrahim
    Foster, Matthew C.
    Sallman, David A.
    Sweet, Kendra L.
    Rizzieri, David A.
    Sayre, Peter H.
    Advani, Anjali S.
    Emadi, Ashkan
    Wieduwilt, Matthew J.
    Vey, Norbert
    Ciceri, Fabio
    Carrabba, Matteo Giovanni
    Moyo, Tamara
    Church, Sarah E.
    Rettig, Michael P.
    Arellano, Martha L.
    Godwin, John E.
    Lowenberg, Bob
    Huls, Gerwin
    Ravandi, Farhad
    Muth, John
    Tran, Kathy
    Jongen-Lavrencic, Mojca
    Timmeny, Erin
    Topp, Max S.
    Paolini, Stefania
    Guo, Kuo
    Curtis, Teia
    Zhao, Jian
    Vadakekolathu, Jayakumar
    Wigginton, Jon M.
    Bonvini, Ezio
    Rutella, Sergio
    Walter, Roland B.
    Davidson-Moncada, Jan K.
    DiPersio, John F.
    BLOOD, 2019, 134
  • [9] Ex-vivo exposure-response characterization of antitumor activity of anti CD123 X CD3 DuoBody in primary acute myeloid leukemia (AML) bone marrow samples
    Singh, Indrajeet
    Parab, Nikita
    Syed, Khaja
    Jiang, Xiling
    Sun, Yu-Nien
    Huang, Fei
    Sasser, Kate
    Kalota, Anna
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S40 - S40
  • [10] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Westervelt, Peter
    Cortes, Jorge E.
    Altman, Jessica K.
    Long, Meixiao
    Oehler, Vivian G.
    Gojo, Ivana
    Guenot, Jeanmarie
    Chun, Patrick
    Roboz, Gail J.
    BLOOD, 2019, 134
12